美研究人员打破常规寻找艾滋病疫苗研发新途径

美研究人员打破常规寻找艾滋病疫苗研发新途径

 
 
 
 
 

美研究人员打破常规寻找艾滋病疫苗研发新途径
2009年05月19日 10:52 来源:科技日报 
  来自美国的一个研究小组5月17日称,他们绕过常规途径开发出了一种新型艾滋病疫苗,并成功使猕猴对一种与艾滋病病毒极为相似的猿猴免疫缺陷病毒(SIV)产生了免疫。该成果为人类艾滋病疫苗的研究带来了新希望。相关研究当日发表在《自然•医学》杂志网络版上。 

  负责该研究的美国费城儿童医院首席科学家菲利普•约翰逊博士称,过去研制艾滋病疫苗的尝试大多集中于使用一种物质激活人体免疫系统,使其产生抗体,以期消灭病毒,防止感染。然而临床试验的结果并不乐观,正如人体自身不能产生有效反应来防止艾滋病感染一样,艾滋病疫苗也无法引起保护性免疫反应。

  菲利普•约翰逊博士和他的研究伙伴、俄亥俄全美儿童医院的病毒学家里德•克拉克博士经过十余年的摸索,采取了跨越式战略,绕过了先前研究所关注的天然免疫系统反应,另辟蹊径,采用基因转移技术,达到防止感染艾滋病的目的。

  该研究分为两个过程:在第一阶段,研究人员首先创建一种被称之为附着性免疫蛋白(im鄄munoadhesins)的类抗体蛋白,这种蛋白将起到绑定SIV并阻断其感染健康细胞的作用。在证实其能够有效防止SIV感染后,研究人员通过基因转移技术,将其置入另一种中转病毒。他们选取了一种被称为腺群病毒(AAV)的病毒作为携带该类抗体蛋白的中转病毒,因为它能有效地插入DNA中,也容易进入猕猴细胞和人体细胞。

  在第二阶段,研究人员将携带类抗体蛋白的腺群病毒注射入猕猴肌肉,这样植入的基因就会制造出附着性免疫蛋白,进入到血液循环系统。1个月后,再对接受过免疫的猕猴注入能导致猕猴艾滋病的SIV病毒。结果表明,绝大多数接受过疫苗注射的猕猴都对SIV感染产生了免疫,所有猕猴均未出现艾滋病症状。实验一年后,在接受过免疫的猕猴血液中还存有较高浓度的类SIV抗体。而对照组中,未进行免疫的猕猴则均被SIV感染,且三分之二死于艾滋病并发症。

  约翰逊博士指出,这种方法还可用于疟疾等传染病的防治。而要想使该方法成为防止人类艾滋病蔓延的有效措施,还需对抗HIV分子,包括人类单克隆抗体等,进行更深入的研究。
 

U.S. researchers find an AIDS vaccine to break the conventional means of research and development of new
At 10:52 on May 19, 2009 Source: Science and Technology Daily
From the United States, a research group said May 17 that they bypass the conventional way to develop a new type of AIDS vaccine, and the success of a monkey with AIDS virus is very similar to the simian immunodeficiency virus (SIV) resulted in immune . The results for human AIDS vaccine research has brought new hope. The date of the relevant research published in "Nature • Medicine" magazine online.

Responsible for the study of Children's Hospital of Philadelphia, Chief Scientist Dr. Philip • Johnson, in the past to try to develop an AIDS vaccine have focused on the use of a substance to activate the body's immune system to produce antibodies, with a view to eliminate the virus and prevent infection. However, the results of clinical trials are not optimistic, as the body's own can not produce an effective response to prevent HIV infection, the AIDS vaccine can not cause a protective immune response.

• Dr. Philip Johnson and his research partner, the National Children's Hospital Ohio virologist Dr. Clark Reed • After more than ten years of exploration, to take the great-leap-forward strategy, bypassing the previous Institute of concern to the natural immune system response, open a new path, the use of gene transfer technology, to achieve the purpose of preventing HIV infection.

The study is divided into two processes: In the first phase, the researchers were the first to create an immune protein called attachment (im Juan munoadhesins) the type of antibody protein, the protein will play SIV binding and blocking its The role of infection in healthy cells. Confirmed its ability to effectively prevent SIV infection, the researchers through gene transfer technology to transfer the virus into another. They selected a group of viruses known as adenovirus (AAV) carrying the virus, such as antibody protein transit viruses, because it effectively insert DNA, but also easier access to the monkey cells and human cells.

In the second phase, researchers will be carrying the adenovirus type of antibody protein group virus was injected into monkeys muscle, so that the implanted gene will produce the immune adhesion proteins into the circulatory system. 1 month after immunization of the monkeys received injection can lead to the SIV AIDS virus monkeys. The results showed that the vast majority have received vaccination against SIV infection in monkeys resulted in immunization, all monkeys had no symptoms of AIDS. One year after the experiment, received immunity in monkeys also have higher blood concentrations of type SIV antibodies. The control group did not immunize the monkeys were then infected with SIV, and two-thirds died of AIDS complications.

Dr. Johnson pointed out that this method can also be used for malaria prevention and treatment of infectious diseases. And the methods to prevent the spread of human AIDS and effective measures needed to combat HIV, including the human monoclonal antibodies and so on, for more in-depth research.
 
 
 
 
 

[ 作者:佚名    转贴自:本站原创    点击数:196    更新时间:2009-5-20    文章录入:nnb ]

 

个人简介
协和专家门诊部艾滋病治疗中心主任、教授、专家,中医药疑难病专治网站长等。论文《艾滋病中医论治探析》登载《中国性病艾滋病》2003版杂志,发明的艾滋病治疗新药康生丹自2002年临床应用至今疗效显著,现有中国唯一艾滋病新药3代…
每日关注 更多
赞助商广告